By early 2026, surveys indicate that approximately 1 in 8 American adults have used a GLP-1 medication at some point. That’s over 40 million people. To put that in perspective: that’s more people than have used Prozac, Viagra, or any statin at this stage of those drugs’ lifecycles.
GLP-1 receptor agonists have gone from a specialized diabetes treatment to one of the fastest-adopted drug classes in pharmaceutical history. Understanding how we got here—and where it’s heading—matters whether you’re considering treatment, already on it, or just trying to make sense of the phenomenon.
The Numbers in Context
- • ~40 million U.S. adults have tried a GLP-1 medication
- • ~15 million are currently taking one (many discontinued due to cost or access)
- • $50+ billion in combined annual revenue for Novo Nordisk and Eli Lilly from GLP-1 drugs
- • 74% of American adults have overweight or obesity (the eligible population)
The Timeline: How We Got Here
2005–2017: The Diabetes Era
GLP-1 receptor agonists (exenatide, then liraglutide) were initially developed and prescribed exclusively for type 2 diabetes. They were effective but niche—most endocrinologists saw them as second or third-line options behind metformin and insulin.
2017–2021: The Pivot to Weight Loss
Ozempic (semaglutide) launched for diabetes in 2017, and patients immediately noticed significant weight loss as a “side effect.” Novo Nordisk began the STEP trial program to study semaglutide specifically for weight management. In 2021, Wegovy (semaglutide 2.4mg) received FDA approval for chronic weight management—the first truly effective obesity medication since the market had been burned by fen-phen decades earlier.
2022–2023: Celebrity Exposure and Social Media
Celebrity use of Ozempic (and media coverage of it) launched GLP-1 medications into mainstream awareness. Social media platforms—particularly TikTok—became filled with before-and-after transformations. Demand exploded, creating nationwide shortages of both semaglutide and tirzepatide.
2023–2024: The Compounding Boom
Shortages triggered the FDA’s shortage exception, allowing compounding pharmacies to produce semaglutide and tirzepatide. This dramatically expanded access and lowered costs, bringing GLP-1 medications within reach of millions who couldn’t afford brand-name prices or get insurance coverage.
2025–2026: Maturation
Shortages resolved, regulatory enforcement tightened, and the market professionalized. New formulations (Wegovy HD 7.2mg, oral semaglutide for weight loss), new indications (heart failure, sleep apnea, kidney disease, liver disease), and new pipeline drugs (retatrutide, amycretin) expanded the clinical story well beyond weight loss.
Why the Adoption Rate Is So High
Several factors converged to drive unprecedented adoption:
- They work: 15–25% average weight loss is a fundamentally different outcome than anything previously available. For the first time, a medication produces results that patients can see and feel
- The obesity epidemic is massive: 74% of American adults have overweight or obesity. The addressable population is enormous
- Beyond-weight-loss benefits: Cardiovascular risk reduction, kidney protection, liver disease treatment, and potential addiction applications give providers more reasons to prescribe
- Telehealth lowered barriers: Online providers made it possible to get a prescription without visiting a specialist in person
- Compounding expanded access: $150–400/month compounded options put treatment within reach for the uninsured and underinsured
- Cultural destigmatization: As more people openly discussed using GLP-1 medications, the stigma around medical weight management decreased
What This Scale Means
For Healthcare
Health economists are modeling scenarios where widespread GLP-1 adoption reduces downstream costs for diabetes, heart disease, joint replacements, and other obesity-related conditions. Some employers and insurers are expanding coverage because the math favors paying for prevention over paying for consequences.
For the Food Industry
With millions of people eating 20–30% less, food companies are adapting. Protein-focused products, smaller portion packaging, and functional foods are growing while traditional snack and fast food categories face headwinds. This is a slow-motion disruption of one of the largest industries in the world.
For Drug Development
The success of GLP-1 medications has triggered a pipeline rush. Dozens of next-generation compounds are in development—oral versions, longer-acting formulations, multi-receptor agonists, and muscle-preserving variants. The competition will drive prices down and outcomes up.
For Patients
Scale brings advantages: more provider options, more research, more insurance coverage pressure, and eventually, generic competition. The more people use these medications, the better the long-term safety data becomes and the harder it is for insurers to deny coverage for what is clearly a mainstream medical treatment.
The Access Gap Remains
Despite the headline number, access remains uneven. Cost is still the primary barrier—brand-name medications are $1,000+/month, many insurance plans don’t cover weight management indications, and Medicare only recently began covering GLP-1s for obesity. Compounded options help bridge the gap, but they face ongoing regulatory uncertainty.
What’s Next
If current trends continue, the 1-in-8 number will look conservative within a few years. Analysts project that by 2030, GLP-1 medications could be prescribed to over 30 million concurrent users in the U.S. alone. Key drivers include Canadian generic semaglutide (launching 2026), expanding FDA indications, potential U.S. generic competition, and growing employer/insurance coverage.
We are watching a generational shift in how medicine treats obesity and its related conditions. The numbers tell the story: this isn’t a trend. It’s a new standard of care.